Heart Attack

Clinical Trial Finder

Many patients with heart disease are interested in participating in the latest research regarding their condition. This Clinical Trial Finder can help you—or a loved one—easily find ongoing cardiovascular clinical research trials for which you might qualify. This list is a service of the U.S. National Institutes of Health called clinicaltrials.gov, a database of publicly and privately supported clinical studies.

Simply click on the trial below that interests you to learn how you might participate.

Optical Coherence Tomography in Patients With Acute Myocardial Infarction and Nonobstructive Coronary Artery Disease

Condition:   Myocardial Infarction
Intervention:   Device: OCT and CMR imaging
Sponsor:   Institute of Cardiology, Warsaw, Poland
Recruiting - verified May 2016

Prophylactic Substrate Ablation in Post-myocardial Patients Undergoing Defibrillator Implantation.

Conditions:   Heart Failure;   Myocardial Infarction;   Ventricular Tachycardia
Intervention:   Procedure: Ventricular tachycardia substrate ablation
Sponsors:   Spyridon Deftereos;   Biosense Webster, Inc.
Not yet recruiting - verified May 2016

STrategic Reperfusion in Elderly Patients Early After Myocardial Infarction

Condition:   Myocardial Infarction
Interventions:   Drug: Tenecteplase;   Drug: Clopidogrel;   Procedure: Coronary angiography;   Procedure: Primary PCI
Sponsors:   Katholieke Universiteit Leuven;   Boehringer Ingelheim;   Life Sciences Research Partners;   Fund for Clinical Cardiovascular Research at LRD
Not yet recruiting - verified May 2016

The Proteins of the Contact Activation System

Conditions:   Factor XI Deficiency;   Factor XII Deficiency
Intervention:   Other: Global Haemostasis assays
Sponsor:   Hospices Civils de Lyon
Recruiting - verified May 2016

Anticoagulants Comparative Benefit-risk Ratio in Real Life

Condition:   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Completed - verified May 2016

Carotid Artery Stenting Without Protection

Condition:   Carotid Arteries
Interventions:   Device: CAS with CPD;   Other: CAS without CPD
Sponsor:   Acibadem University
Recruiting - verified May 2016

Combination of Metformine/Inulin Versus Metformin on Prostate Benign Hyperplasia in Metabolic Syndrome

Condition:   Metabolic Syndrome
Interventions:   Drug: Metformin;   Dietary Supplement: Agave inulin;   Other: Placebo of agave inulin;   Other: Metformin placebo
Sponsor:   Centro Universitario de Ciencias de la Salud, Mexico
Completed - verified May 2016

Text Messages and Blood Pressure Control

Condition:   Hypertension
Intervention:   Other: Bi-directional texting
Sponsor:   University of Iowa
Recruiting - verified May 2016

Comparison Between Standard and Ultrasound Integrated Approach for Risk Stratification of Syncope in the Emergency Department

Condition:   Syncope
Intervention:  
Sponsor:   University of Turin, Italy
Recruiting - verified May 2016

Late Stent Strut Apposition and Coverage After Drug-Eluting Stent Implantation by OCT in Patients With AMI

Conditions:   Coronary Artery Disease;   Coronary Disease;   Myocardial Ischemia;   Arterial Occlusive Diseases;   Arteriosclerosis;   Cardiovascular Diseases;   Heart Diseases;   Vascular Diseases
Interventions:   Device: Everolimus-Eluting stent;   Device: Zotarolimus-Eluting stent
Sponsor:   Keimyung University Dongsan Medical Center
Recruiting - verified May 2016

Safety and Vascular Remodelling After BVS Implantation for Stenotic or Occluded Lesions in Children and Young Adults With KD.

Condition:   Kawasaki Disease
Intervention:   Device: Bioresorbable Vascular Scaffold
Sponsor:   National Taiwan University Hospital
Recruiting - verified May 2016

Self-apposing Stentys Stents Registry

Condition:   Coronary Artery Disease
Intervention:  
Sponsor:   Azienda Ospedaliera Città della Salute e della Scienza di Torino
Not yet recruiting - verified May 2016

Optimizing Strategy of Coronary Revascularization in Patients With Multivessel Lesions Combined Heart Failure

Condition:   Heart Failure Due to Coronary Artery Disease
Interventions:   Procedure: Coronary Artery Bypass Grafting;   Procedure: Percutaneous Coronary Intervention;   Procedure: Hybrid Coronary Revascularization
Sponsor:   Shanghai Jiao Tong University School of Medicine
Recruiting - verified May 2016

The IPED (Investigation of Palpitations in the ED) Study

Conditions:   Presyncope;   Arrhythmias, Cardiac;   Tachycardia, Supraventricular;   Atrial Fibrillation
Intervention:   Device: AliveCor Heart Monitor
Sponsor:   NHS Lothian
Not yet recruiting - verified February 2016

Mindfulness & Stress Management Study for Cardiac Patients

Conditions:   Heart Diseases;   Heart Failure;   Myocardial Infarction;   Chronic Stable Angina;   Coronary Artery Bypass;   Angioplasty
Intervention:   Behavioral: Mindfulness-Based Stress Reduction (MBSR).
Sponsors:   University of Minnesota - Clinical and Translational Science Institute;   Fairview Health Services
Recruiting - verified May 2016

Percutaneous Coronary Intervention With the Angiolite Drug-eluting Stent: an Optical Cohenrece Tomography Study

Condition:   Coronary Heart Disease
Intervention:   Device: Angiolite stent
Sponsors:   Josep Rodes-Cabau;   iVascular
Recruiting - verified May 2016

Safety and Efficacy Study of a Protease Activated Receptor-4 Antagonist Being Tested to Reduce the Chances of Having Additional Strokes or "Mini Strokes"

Condition:   Thrombosis
Interventions:   Drug: BMS-986141;   Drug: Aspirin;   Other: Placebo
Sponsor:   Bristol-Myers Squibb
Recruiting - verified January 2016

The Impact of Text Messaging on Medication Adherence and Exercise Regimen Among Post-myocardial Infarction Patients

Condition:   Myocardial Infarction
Interventions:   Behavioral: Text message reminder for medication adherence;   Behavioral: Text message reminder for exercise regimen
Sponsors:   Brigham and Women's Hospital;   University of Waterloo
Completed - verified May 2016

Remote Ischaemic Conditioning After Stroke Trial (ReCAST-2)

Condition:   Stroke
Interventions:   Procedure: Remote ischaemic conditioning;   Procedure: Sham
Sponsor:   University of Nottingham
Not yet recruiting - verified May 2016

A Study of the ReCor Medical Paradise System in Clinical Hypertension

Conditions:   Hypertension;   Vascular Diseases
Interventions:   Device: The Paradise® Renal Denervation Ultrasound System;   Device: Sham Procedure
Sponsor:   ReCor Medical, Inc.
Recruiting - verified March 2016

AZD9668, an Oral Neutrophil Elastase Inhibitor, in Bronchiolitis Obliterans Syndrome After Allogeneic Hematopoietic Stem Cell Transplantation

Conditions:   Chronic Graft vs Host Disease;   Chronic Graft-Versus-Host-Disease;   Bronchiolitis Obliterans Syndrome
Intervention:   Drug: AZD9668
Sponsor:   National Cancer Institute (NCI)
Recruiting - verified May 2016

Impact of Morphine Treatment on Platelet Inhibition in Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Interventions:   Drug: Morphinhydrochloricum;   Drug: Metoclopramide;   Drug: Ticagrelor;   Drug: Isotonic sodium chloride
Sponsor:   University of Luebeck
Recruiting - verified May 2016

Nesiritide in Uncontrolled Hypertension

Condition:   Hypertension
Interventions:   Drug: Nesiritide;   Drug: Placebo
Sponsors:   Oslo University Hospital;   University of Oslo;   University Hospital, Akershus
Recruiting - verified December 2015

Performing a Low-dose, Whole-body Angiography as the First Element of an Imaging Assessment Following Stroke / TIA

Conditions:   Stroke;   Ischemic Attack, Transient
Interventions:   Other: Routine Imaging Assessment;   Device: LDWBA first (CT scan)
Sponsor:   Centre Hospitalier Universitaire de Nīmes
Not yet recruiting - verified May 2016

Global Study Comparing a rivAroxaban-based Antithrombotic Strategy to an antipLatelet-based Strategy After Transcatheter aortIc vaLve rEplacement to Optimize Clinical Outcomes

Condition:   Transcatheter Aortic Valve Replacement
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Acetylsalicylic acid;   Drug: Clopidogrel
Sponsors:   Bayer;   Janssen Research & Development, LLC
Recruiting - verified May 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and the Clinical Diagnosis of Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2016

Efficacy and Safety of Finerenone in Subjects With Type 2 Diabetes Mellitus and Diabetic Kidney Disease

Condition:   Diabetic Kidney Disease
Interventions:   Drug: Finerenone (BAY94-8862);   Drug: Placebo
Sponsor:   Bayer
Recruiting - verified May 2016

Efficacy and Safety of Rivaroxaban in Reducing the Risk of Major Thrombotic Vascular Events in Subjects With Symptomatic Peripheral Artery Disease Undergoing Peripheral Revascularization Procedures of the Lower Extremities

Condition:   Peripheral Artery Disease
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Rivaroxaban-Placebo
Sponsors:   Bayer;   Janssen Research & Development, LLC;   Colorado Prevention Center
Recruiting - verified May 2016

Platelet Reactivity in Acute Non-disabling Cerebrovascular Events

Conditions:   Stroke;   Ischemic Attack, Transient
Interventions:   Drug: Ticagrelor and Acetylsalicylic acid;   Drug: Clopidogrel and Acetylsalicylic acid
Sponsors:   Ministry of Science and Technology of the People´s Republic of China;   Beijing Municipal Science & Technology Commission
Recruiting - verified May 2016

PeRiodontal Treatment to Eliminate Minority InEquality and Rural Disparities in Stroke

Conditions:   Periodontal Disease;   Stroke;   TIA
Interventions:   Procedure: Intensive dental treatment;   Procedure: Standard dental treatment;   Drug: Arestin
Sponsors:   University of South Carolina;   University of North Carolina, Chapel Hill
Recruiting - verified May 2016

Study of Rivaroxaban Use and Potential Adverse Outcomes in Routine Clinical Practice (Sweden)

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Rivaroxaban (Xarelto, BAY59-7939);   Drug: Standard of care drugs
Sponsor:   Bayer
Recruiting - verified May 2016

Comparison of Anticoagulation for All-comers Undergoing Percutaneous Coronary Revascularization Trial

Condition:   Percutaneous Coronary Intervention
Interventions:   Drug: Bivalirudin;   Drug: Unfractionated heparin
Sponsor:   Kaiser Permanente
Terminated - verified May 2015

A Study in Asthma Patients to Evaluate Efficacy, Safety and Tolerability of 14 Days Once Daily Inhaled Interferon Beta-1a After the Onset of Symptoms of an Upper Respiratory Tract Infection

Condition:   Asthma
Interventions:   Drug: Interferon beta-1a Nebuliser solution 48 μg/mL;   Drug: Placebo
Sponsor:   AstraZeneca
Recruiting - verified May 2016

Safety and Efficacy Evaluation of Intracoronary Infusion of Allogeneic Human Cardiac Stem Cells in Patients With AMI

Condition:   Acute Myocardial Infarction
Interventions:   Other: Allogeneic human cardiac stem cells (CSCs);   Other: Human Serum Albumin-HSA 5%
Sponsors:   Coretherapix;   European Commission;   Universitaire Ziekenhuizen Leuven;   Saint-Louis Hospital, Paris, France;   Hospital General Universitario Gregorio Marañon;   Complejo Hospitalario de Navarra;   Hospital Clínico Universitario de Valladolid;   Hospital Donostia;   Hospital Clínico Universitario de Valencia;   Hospital Universitario de Salamanca;   Hospital Universitario Virgen de la Victoria
Active, not recruiting - verified May 2016

Eplerenone in Heart Failure Treatment

Conditions:   Heart Failure;   Acute Myocardial Infarction;   Hypertension
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Completed - verified May 2016

Diagnostic Imaging Strategies for Patients With Stable Chest Pain and Intermediate Risk of Coronary Artery Disease

Condition:   Coronary Artery Disease
Interventions:   Procedure: Computed tomography angiography (cardiac CT);   Procedure: Invasive coronary angiography (ICA)
Sponsor:   Charite University, Berlin, Germany
Recruiting - verified May 2016

Evaluating the Use of Pitavastatin to Reduce the Risk of Cardiovascular Disease in HIV-Infected Adults

Conditions:   HIV Infections;   Cardiovascular Diseases
Interventions:   Drug: Pitavastatin;   Drug: Placebo
Sponsors:   National Institute of Allergy and Infectious Diseases (NIAID);   National Heart, Lung, and Blood Institute (NHLBI);   Kowa Pharmaceuticals America, Inc.
Recruiting - verified May 2016

BIO monitorinG in Patients With Preserved Left ventricUlar Function AfteR Diagnosed Acute Myocardial Infarction

Condition:   Acute Myocardial Infarction
Intervention:   Device: BioMonitor
Sponsor:   Biotronik SE & Co. KG
Recruiting - verified May 2016

Ticagrelor Pharmacokinetics in NSTEMI

Condition:   Myocardial Infarction
Intervention:   Drug: Ticagrelor
Sponsors:   Karolinska University Hospital;   AstraZeneca
Completed - verified May 2016

Utilization of Ticagrelor in the Upstream Setting for Non-ST-Segment Elevation Myocardial Infarction (UPSTREAM): An ED-Based Clinical Registry

Condition:   Acute Coronary Syndromes
Intervention:   Other: Non-Interventional Study
Sponsor:   AstraZeneca
Recruiting - verified May 2016

Exploring the Mechanism of the Plaque Rupture in Acute Myocardial Infarction

Conditions:   Acute Coronary Syndrome;   Myocardial Infarction;   Plaque, Atherosclerotic;   Rupture, Spontaneous
Intervention:  
Sponsors:   Seoul National University Hospital;   HeartFlow, Inc.;   Kyoto University, Graduate School of Medicine;   Inje University;   Keimyung University Dongsan Medical Center;   Ulsan University Hospital;   Wakayama Medical University;   Aarhus University Hospital
Active, not recruiting - verified May 2016

PLATINUM Diversity

Conditions:   Atherosclerosis;   Coronary Artery Disease
Intervention:   Device: Percutaneous coronary intervention (Promus PREMIER)
Sponsor:   Boston Scientific Corporation
Active, not recruiting - verified May 2016

Dabigatran Etexilate for Secondary Stroke Prevention in Patients With Embolic Stroke of Undetermined Source (RE-SPECT ESUS)

Conditions:   Stroke;   Secondary Prevention
Interventions:   Drug: optional ASA as comedication;   Drug: placebo to ASA;   Drug: placebo to optional ASA as comedication;   Drug: placebo to dabigatran etexilate;   Drug: ASA 100 mg;   Drug: dabigatran etexilate
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

MOMENTUM 3 IDE Clinical Study Protocol

Condition:   Advanced Refractory Left Ventricular Heart Failure
Interventions:   Device: HeartMate 3 LVAS;   Device: HeartMate II LVAS
Sponsors:   Thoratec Corporation;   St. Jude Medical
Recruiting - verified May 2016

AOP2014 in Patients With Polycythemia Vera Who Previously Participated in the PROUD-PV Study.

Condition:   Polycythemia Vera
Intervention:   Drug: Pegylated-Proline-interferon alpha-2b
Sponsors:   AOP Orphan Pharmaceuticals AG;   PharmaEssentia (Co-Sponsor for USA)
Recruiting - verified May 2016

Intravascular Ultrasound Guided Drug Eluting Stent Implantation in "All-comers" Coronary Lesions

Condition:   Coronary Artery Disease
Interventions:   Procedure: Angiography;   Procedure: IVUS;   Procedure: DES implantation
Sponsor:   The First Affiliated Hospital with Nanjing Medical University
Recruiting - verified May 2016

Pre-hospital Anti-fibrinolytics for Traumatic Coagulopathy and Haemorrhage (The PATCH Study)

Conditions:   Wounds and Injuries;   Acute Coagulopathy
Interventions:   Drug: Tranexamic Acid;   Drug: Placebo
Sponsors:   National Trauma Research Institute;   National Health and Medical Research Council, Australia
Recruiting - verified May 2016

Comparison of Agent™ and SeQuent® Please Paclitaxel Coated Balloon Catheters in Coronary In-stent Restenosis (AGENT-ISR)

Conditions:   Coronary Artery Disease;   Coronary Restenosis;   Coronary Atherosclerosis;   Coronary Arteriosclerosis
Interventions:   Device: Agent Paclitaxel-coated balloon;   Device: SeQuent® Please Paclitaxel-coated Balloon
Sponsor:   Hemoteq AG
Active, not recruiting - verified May 2016

TEAMS (Troponin Elevation After Major Surgery) Study

Conditions:   Perioperative Myocardial Infarction;   Disability
Intervention:  
Sponsor:   University Health Network, Toronto
Active, not recruiting - verified November 2015

Optimal Anticoagulation for Higher Risk Patients Post-Catheter Ablation for Atrial Fibrillation Trial

Conditions:   Atrial Fibrillation;   Stroke
Interventions:   Drug: Rivaroxaban;   Drug: Acetylsalicylic acid
Sponsors:   Ottawa Heart Institute Research Corporation;   Canadian Institutes of Health Research (CIHR);   Bayer;   Biotronik SE & Co. KG
Recruiting - verified May 2016

Antiplatelet Therapy Following Stent Implantation

Conditions:   Acute Myocardial Infarction;   Coronary Syndrome;   Angina, Unstable
Intervention:  
Sponsor:   Elpen Pharmaceutical Co. Inc.
Completed - verified May 2016

Microvascular Disease Exercise Trial

Condition:   Coronary Microvascular Disease
Interventions:   Behavioral: Exercise Program;   Drug: Medical Therapy
Sponsors:   University of Virginia;   Astellas Pharma Global Development, Inc.;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2016

Study Of The Blood Thinner, Apixaban, For Patients Who Have An Abnormal Heart Rhythm (Atrial Fibrillation) And Expected To Have Treatment To Put Them Back Into A Normal Heart Rhythm (Cardioversion)

Condition:   Atrial Fibrillation
Interventions:   Drug: Apixaban;   Drug: Parenteral heparin and/or oral Vitamin K antagonist
Sponsors:   Pfizer;   Bristol-Myers Squibb
Recruiting - verified May 2016

Multicenter Comparison of Early and Late Vascular Responses to Everolimus-eluting Cobalt-CHromium Stent and Platelet AggregatioN studIeS for TreatMent of Acute Myocardial InfarctionTreatment of ST-elevation Acute Myocardial Infarction

Condition:   Coronary Artery Disease
Intervention:   Device: cobalt-chromium everolimus-eluting stent (CoCr-EES)
Sponsor:   Iwate Medical University
Active, not recruiting - verified May 2016

The Evaluation of Bococizumab (PF-04950615; RN316) in Reducing the Occurrence of Major Cardiovascular Events in High Risk Subjects

Condition:   Cardiovascular Disease
Interventions:   Drug: bococizumab (PF-04950615);   Drug: Placebo
Sponsor:   Pfizer
Recruiting - verified May 2016

Testing Responsiveness to Platelet Inhibition on Chronic Antiplatelet Treatment For Acute Coronary Syndromes Trial

Condition:   Acute Coronary Syndrome
Interventions:   Drug: Prasugrel;   Drug: Clopidogrel
Sponsor:   Klinikum der Universitaet Muenchen
Active, not recruiting - verified May 2016

Cardiovascular and Renal Microvascular Outcome Study With Linagliptin in Patients With Type 2 Diabetes Mellitus (CARMELINA)

Condition:   Diabetes Mellitus, Type 2
Interventions:   Drug: Placebo;   Drug: Linagliptin
Sponsors:   Boehringer Ingelheim;   Eli Lilly and Company
Recruiting - verified May 2016

A Study to Assess the Effectiveness and Safety of Rivaroxaban in Reducing the Risk of Death, Myocardial Infarction or Stroke in Participants With Heart Failure and Coronary Artery Disease Following an Episode of Decompensated Heart Failure

Conditions:   Heart Failure;   Coronary Artery Disease
Interventions:   Drug: Rivaroxaban;   Drug: Placebo;   Other: Standard of care for heart failure and coronary artery disease
Sponsors:   Janssen Research & Development, LLC;   Bayer
Recruiting - verified May 2016

GLP-1 and Hypoglycemia

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Glucagon-Like Peptide- 1 (GLP-1) infusion;   Other: Placebo Comparator: Saline Infusion
Sponsor:   University of Maryland
Recruiting - verified May 2016

Chronic Remote Ischemic Conditioning to Modify Post-MI Remodeling

Condition:   Myocardial Infarction
Intervention:   Device: Auto Remote Ischemic Conditioning (AutoRIC) device
Sponsors:   The Hospital for Sick Children;   University Health Network, Toronto;   Sunnybrook Health Sciences Centre;   St. Michael's Hospital, Toronto
Withdrawn - verified May 2016

A Study Comparing Cardiovascular Effects of Ticagrelor and Clopidogrel in Patients With Peripheral Artery Disease

Condition:   Peripheral Artery Disease
Interventions:   Drug: Ticagrelor;   Drug: Clopidogrel
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2016

Predictive Value of Neovascularization Within Asymptomatic Carotis Stenosis on CEUS

Condition:   Carotid Stenosis
Intervention:  
Sponsors:   University Hospital, Basel, Switzerland;   Swiss National Science Foundation
Recruiting - verified May 2016

A Study to Assess Cardiovascular Outcomes Following Treatment With Omarigliptin (MK-3102) in Participants With Type 2 Diabetes Mellitus (MK-3102-018)

Condition:   Type 2 Diabetes Mellitus
Interventions:   Drug: Omarigliptin;   Drug: Placebo
Sponsor:   Merck Sharp & Dohme Corp.
Terminated - verified May 2016

GLORIA-AF Registry Program (Phase II/III - EU/EEA Member States)

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

Acute Versus Subacute Angioplasty in Patients With NON-ST-Elevation Myocardial Infarction

Condition:   Myocardial Infarction
Intervention:   Procedure: Group I: Primary PCI
Sponsor:   Aarhus University Hospital Skejby
Terminated - verified May 2016

A Post Marketing Surveillance to Evaluate the Safety and Efficacy of Brilinta

Condition:   Acute Coronary Syndromes
Intervention:  
Sponsor:   AstraZeneca
Active, not recruiting - verified May 2016

Cardiovascular Inflammation Reduction Trial

Condition:   Cardiovascular Disease
Interventions:   Drug: Methotrexate;   Drug: Placebo
Sponsors:   Brigham and Women's Hospital;   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2016

Primary Reperfusion Secondary Stenting Trial

Condition:   ST-elevation Myocardial Infarction
Intervention:   Procedure: Percutaneous coronary intervention
Sponsor:   Montreal Heart Institute
Recruiting - verified May 2016

Role of Cerebral Oximetry In Reducing Delirium After Complex Cardiac Surgery

Condition:   Cardiac Disease
Interventions:   Device: Cerebral oximetry monitor (The INVOS® Cerebral/Somatic Oximeter);   Other: An alarm threshold at 75% of the baseline rSO2 value
Sponsor:   University Health Network, Toronto
Active, not recruiting - verified May 2016

International Study of Comparative Health Effectiveness With Medical and Invasive Approaches (ISCHEMIA)

Conditions:   Cardiovascular Diseases;   Coronary Disease;   Coronary Artery Disease;   Heart Diseases;   Myocardial Ischemia
Interventions:   Procedure: cardiac catheterization;   Procedure: coronary artery bypass graft surgery;   Procedure: percutaneous coronary intervention;   Behavioral: Lifestyle;   Drug: Medication
Sponsors:   New York University School of Medicine;   New York University;   Stanford University;   National Heart, Lung, and Blood Institute (NHLBI);   Albany Stratton VA Medical Center;   Cedars-Sinai Medical Center;   Columbia University;   Duke University;   East Carolina University;   Emory University;   Harvard University;   Massachusetts General Hospital;   Montreal Heart Institute;   University of British Columbia;   University of Missouri, Kansas City;   Vanderbilt University
Recruiting - verified May 2016

GLORIA-AF Registry Program - Second and Third Phases

Conditions:   Stroke;   Atrial Fibrillation
Intervention:  
Sponsor:   Boehringer Ingelheim
Recruiting - verified May 2016

A Open-Label Study Of CP-690,550 As Long-Term Therapy (48 Weeks) In Subjects With Crohn's Disease

Condition:   Crohn's Disease
Interventions:   Drug: CP-690,550;   Drug: CP-690,550
Sponsor:   Pfizer
Recruiting - verified May 2016

The "Virtual" Multicenter Spontaneous Coronary Artery Dissection (SCAD) Registry

Conditions:   Spontaneous Coronary Artery Dissection;   SCAD
Intervention:  
Sponsor:   Mayo Clinic
Recruiting - verified May 2016

Early Thienopyridine Treatment to Improve Primary Percutaneous Coronary Intervention in Patients With Acute Myocardial Infarction

Conditions:   Myocardial Infarction;   STEMI
Interventions:   Drug: prasugrel;   Drug: Clopidogrel
Sponsors:   Stiftung Institut fuer Herzinfarktforschung;   Daiichi Sankyo Inc.
Completed - verified May 2016

International Survey of Acute Coronary Syndromes in Transitional Countries

Conditions:   Acute Coronary Syndrome;   Unstable Angina Pectoris;   Myocardial Infarction;   Coronary Disease
Intervention:  
Sponsor:   University of Bologna
Recruiting - verified May 2016

Strict or Liberal Insulin Protocol Following Coronary Artery Bypass Graft (CABG) Surgery

Conditions:   Blood Glucose;   Coronary Artery Bypass;   Insulin;   Coronary Disease
Intervention:   Other: LIBERAL
Sponsor:   Inova Health Care Services
Active, not recruiting - verified May 2016

Trial of Drug Eluting Stent Versus Bare Metal Stent to Treat Coronary Artery Stenosis

Conditions:   Coronary Atherosclerosis;   Angina Pectoris;   Myocardial Infarction
Interventions:   Device: Percutaneous coronary intervention (PCI);   Device: Percutaneous coronary intervention (PCI)
Sponsors:   University of Tromso;   The Research Council of Norway;   The Royal Norwegian Ministry of Health;   Norwegian Council on Cardiovascular diseases
Active, not recruiting - verified May 2016

The Effect of Dietary Sitosterol on Blood Sugar and Cholesterol

Condition:   Sitosterolemia
Intervention:   Behavioral: High/Low Sitosterol
Sponsor:   National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)
Completed - verified May 2016

E-Selectin Nasal Instillation to Prevent Secondary Stroke

Conditions:   Ischemic Attack, Transient;   Transient
Intervention:   Drug: Intransal instillation of E-selectin
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Not yet recruiting - verified May 2016

Safety of SCH 530348 in Subjects Undergoing Non-Emergent Percutaneous Coronary Intervention (Study P03573)

Conditions:   Arterial Obstructive Diseases;   Coronary Disease
Intervention:   Drug: SCH 530348
Sponsor:   Merck Sharp & Dohme Corp.
Completed - verified May 2016

Natural History of Sickle Cell Disease and Other Hemolytic Disorders

Conditions:   Hemoglobin SC Disease;   Hematologic Diseases;   Sickle Cell Anemia;   Hemolytic Anemia
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2016

Technical Development of Cardiovascular Magnetic Resonance Imaging

Condition:   Cardiovascular Disease
Intervention:  
Sponsor:   National Heart, Lung, and Blood Institute (NHLBI)
Recruiting - verified May 2016

Natural History of Stroke: Cause and Development

Conditions:   Nervous System Disease;   Transient Ischemic Attack;   Neurologic Disorders;   Stroke;   Vascular Disease
Intervention:  
Sponsor:   National Institute of Neurological Disorders and Stroke (NINDS)
Recruiting - verified May 2016